Scientists have used 3D models to break down the DNA behavior of cancer cells, in a breakthrough new study which could revolutionize treatment for the disease.
In what is a first for science, a research team led by Dr Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute (IJC), demonstrated how 3D models (known as organoids) can now be used to develop a characterization of the DNA make-up - or the epigenetic fingerprint - of human cancer.
Pubished in Epigenetics , the research validates the use of these 3D samples for cancer research that could deliver new oncology treatments.
Dr Esteller, who is also Chaiman of Genetics at the University of Barcelona, explains:
Frequently, promising cancer therapies fail when applied to patients in the real clinical setting. This occurs despite many of these new treatments demonstrating promising results at the preclinical stage in the lab. One explanation is that many of the tumor models used in early research phases are established cell lines that have been growing for many decades and in two dimension (2D) culture flasks.
These cancer cells might not completely resemble the features of real tumors from patients that expand into three dimensions (3D). Very recently, it has been possible to grow cancers in the laboratories but respecting the 3D structure: these models are called 'organoids'.
We know very little about these cells and if they actually mimic the conformation of the tumor within the body, particularly the chemical behaviors (known as modifications) of DNA that are called epigenetics ("beyond the genetics"), such as DNA methylation.
"What our article solves is this unmet biomedical need in the cancer research field: the characterization of the epigenetic fingerprint of human cancer organoids. The developed study shows that these tumor models can be very useful for the biomedical research community and the pharmaceutical companies developing anti-cancer drugs." Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology